RxDoctor Payments Data

Stuart Spind

Optometrist · Glen Burnie, MDNPI 1003843152

Payments from drug & device makers

$2,908in general payments, 2019–2025

Across 112 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$753
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$400
  • Bausch & Lomb Americas Inc.$321
  • Tarsus Pharmaceuticals, Inc.$251
  • Notal Vision, Inc.$214
  • Coopervision Inc.$199
  • plus $770 from 11 others

What the payments were for

  • Speaking & faculty fees$2147%
  • Food & beverage$2,69593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,908 in reported general payments places this provider in the 85th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$184,504
Medicare patients
643
Services billed
2,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast50$94,801
XdemvyLotilaner43$78,583
RestasisCyclosporine40$73,615
Travoprost30$9,468
Cyclosporine15$4,345
Bepotastine Besilate15$3,947
Epinastine Hcl26$2,901
SimbrinzaBrinzolamide/Brimonidine Tart11$2,713
Tobramycin-DexamethasoneTobramycin/Dexamethasone37$2,177
Latanoprost60$1,309
Prednisolone Acetate20$1,009
Ketorolac Tromethamine21$638
Doxycycline Monohydrate25$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$321$94,80150 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$251$78,58343 claims
AbbVieRestasis$51$73,61540 claims
AlconSimbrinza$753$2,71311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 790 optometrist providers in Maryland.

Other optometrist in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →